IFX-1InflaRx Starts Dosing COVID-19 Patients in Europe

Published 2 April 2020

German biopharmaceutical firm InflaRx has enrolled and dosed the first patient in a clinical study of IFX-1 in Covid-19 patients with severe pneumonia in the Netherlands.
Clinical Trials Arena reports thatIFX-1 is a monoclonal anti-human complement factor C5a antibody designed to inhibit the biological activity of C5a. The drug is not believed to impact the formation of the membrane attack complex (C5b-9).
According to preclinical data, IFX-1 showed ability to control the inflammatory response-related tissue and organ damage via a selective blockade of C5a in the adaptive, randomized, controlled trial.
The drug was found to be well tolerated in around 300 clinical trial participants, according to the company.
IFX-1 is currently in development to treat inflammatory conditions such as hidradenitis suppurativa, ANCA-associated vasculitis, and pyoderma gangraenosum.